Data Sheet 10_Assessing the disease burden of lower respiratory infections attributable to particulate matter pollution: trends from 1990 to 2021 and projections for 2022-2050.pdf by Erman Wu (19021269)

“…Background<p>Particulate matter pollution (PMP) remains a leading risk factor for lower respiratory infections (LRIs) globally. However, the evolving contributions of household air pollution (HAP) versus ambient particulate matter pollution (APMP) across different development stages remain poorly characterized, hindering targeted intervention strategies.…”

Data Sheet 9_Assessing the disease burden of lower respiratory infections attributable to particulate matter pollution: trends from 1990 to 2021 and projections for 2022-2050.pdf by Erman Wu (19021269)

“…Background<p>Particulate matter pollution (PMP) remains a leading risk factor for lower respiratory infections (LRIs) globally. However, the evolving contributions of household air pollution (HAP) versus ambient particulate matter pollution (APMP) across different development stages remain poorly characterized, hindering targeted intervention strategies.…”

Data Sheet 4_Assessing the disease burden of lower respiratory infections attributable to particulate matter pollution: trends from 1990 to 2021 and projections for 2022-2050.pdf by Erman Wu (19021269)

“…Background<p>Particulate matter pollution (PMP) remains a leading risk factor for lower respiratory infections (LRIs) globally. However, the evolving contributions of household air pollution (HAP) versus ambient particulate matter pollution (APMP) across different development stages remain poorly characterized, hindering targeted intervention strategies.…”

NeuN staining of 6-, 9-, and 12-month dLGN sections shows loss of thalamocortical cell bodies in the 5xFAD mice. by Shaylah McCool (20818280)

Study Flowchart. by Jae-Heung Cho (798319)

Subjects:

(A) Cost-effectiveness plane in healthcare system perspectives; (B) Cost-effectiveness acceptability curve in healthcare system perspectives; (C) Cost-effectiveness plane in societ... by Jae-Heung Cho (798319)

Subjects:

Primary and secondary outcomes by treatment and time since randomization. by Jae-Heung Cho (798319)

Subjects:

Entomopathogenic fungi-derived copper nanoparticles (CuNPs) exhibited pupicidal activity against pupae of <i>A</i>. <i>albopictus</i> at 24 and 48h post treatment. by Perumal Vivekanandhan (4863484)

Subjects:

S1 Data - by Perumal Vivekanandhan (4863484)

Subjects:

Entomopathogenic fungi-derived copper nanoparticles (CuNPs) exhibited adulticidal activity against adult of <i>A</i>. <i>albopictus</i> at 24 and 48h post treatment. by Perumal Vivekanandhan (4863484)

Subjects:

Quality of life years after randomization into the <i>Chuna</i> manual therapy and usual care groups. by Jae-Heung Cho (798319)

Subjects:

The response of the <i>A</i>. <i>albopictus</i> larval Glutathione S-transferase (GST) enzyme increased 7.8-fold in response to <i>M</i>. <i>robertsii</i>-derived copper nanopartic... by Perumal Vivekanandhan (4863484)

Subjects:

Changes in outcomes over time. by Jae-Heung Cho (798319)

Subjects:

Baseline characteristics of participants by randomized group. by Jae-Heung Cho (798319)

Subjects:

Schematic diagram of entomopathogen derived copper nanoparticles (CuNPs) and their toxic effects on target and non-target species. by Perumal Vivekanandhan (4863484)

Subjects:

Results of cost-effectiveness analysis of <i>Chuna</i> manual therapy compared with usual care^a. by Jae-Heung Cho (798319)

Subjects:

Entomopathogenic fungi-derived copper nanoparticles (CuNPs) exhibited larvicidal activity against larvae of <i>A</i>. <i>albopictu</i> at 24 and 48h post treatment. by Perumal Vivekanandhan (4863484)

Subjects:

Entomopathogenic fungi-derived copper nanoparticles (CuNPs) exhibited minimal toxicity effects against <i>E</i>. <i>eugeniae</i> at 24 and 48h post treatment. by Perumal Vivekanandhan (4863484)

Subjects:

Entomopathogenic fungi-derived copper nanoparticles (CuNPs) exhibited minimal toxicity effects against <i>A</i>. <i>salina</i> at 24 and 48h post treatment. by Perumal Vivekanandhan (4863484)

Subjects:

Study timetable. by Jae-Heung Cho (798319)

Subjects: